Christopher C. Whalen

Epidemiology & Biostatistics, Global Health Institute
Karen and Jim Holbrook Distinguished Professor in Global Health
UGA Distinguished Research Professor
Director of Global Health Institute

Curriculum Vitae

Epidemiology & Biostatistics, Global Health Institute

Education

MS, Epidemiology and Biostatistics, Case Western Reserve University, 1992

MD, Case Western Reserve University, 1984

BA, English, Stanford University, 1978

Areas of Expertise

Research: tuberculosis, HIV, global health, causal inference, epidemiology, social networks

Teaching: epidemiology, causal inference in epidemiology, infectious disease epidemiology, field epidemiology

Honors, Awards, and Achievements

Alpha Omega Alpha, 1984

Junior Faculty Research Award in for Society of General Internal Medicine, 1991

John S. Diekhoff Award for Distinguished Graduate Teaching, Case Western Reserve University, 1998

Invited plenary speaker, Tuberculosis and HIV Co-Infection Symposium, 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002

Invited speaker, Emmanuel Wolinsky Symposium, 2004

Elected to American Epidemiological Society, 2004

Teacher of the Year Award, Department of Epidemiology and Biostatistics, Case, 2008

Invited Speaker, George Naff Annual Lecture, Case Western Reserve University, 2009

Delta Omega National Honorary Society in Public Health, 2009

Award for Excellence in Research, College of Public Health, University of Georgia, 2011

Distinguished Research Professor Award, University of Georgia, 2012

Elizabeth Hurlock Beckman Award, Elizabeth Hurlock Beckman Trust, 2017

Affiliations

American Epidemiological Society

Society for Epidemiologic Research

Ugandan Society for Health Scientists

Course Instruction

EPID 8500 Infectious Disease Epidemiology

EPID 8040 Randomized Clinical Trials

EPID 8050 Integrating Research Designs

Dr. Whalen offers graduate courses on infectious disease epidemiology and causal inference in epidemiology. In all courses, there is an emphasis on methods and quantitative approaches.

Research Interests

As a physician-epidemiologist Dr. Whalen is interested in reducing the suffering and mortality associated with infectious diseases, especially tuberculosis and HIV infection. He is committed to working in the regions of the world that are most afflicted by these diseases so my research and clinical activities focus on Sub-Saharan Africa, especially Uganda. Dr. Whalen’s research portfolio includes phase II and III clinical trials and large, population-based cohort studies. His main research activities aim to improve current methods and strategies for tuberculosis control and to improve clinical care for tuberculosis among HIV-infected persons. An equal part of my work involves building capacity for research, teaching and clinical care in Africa. He is committed to training future leaders in science and public health in Africa and providing them to equipment, workforce, and infrastructure to be successful.

Selected Publications

Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human-immunodeficiency virus infection after tuberculosis. American journal of respiratory and critical care medicine 1995;151:129-35.

Whalen CC, Nsubuga P, Okwera A, et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. Aids 2000;14:1219-28.

Mayanja-Kizza H, Johnson JL, Hirsch CS, et al. Macrophage-activating cytokines in human immununodeficiency virus type 1-infected and -uninfected patients with pulmonary tuberculosis. The Journal of infectious diseases 2001;183:1805-9.

Mupere E, Zalwango S, Chiunda A, Okwera A, Mugerwa R, Whalen C. Body composition among HIV-seropositive and HIV-seronegative adult patients with pulmonary tuberculosis in Uganda. Annals of epidemiology 2010;20:210-6.

Okwera, A., C. Whalen, F. Byekwaso, M. Vjecha, J. Johnson, R. Huebner, R. Mugerwa and J. Ellner (1994). “Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration.” Lancet 344(8933): 1323-1328.

Mayanja-Kizza H, Jones-Lopez E, Okwera A, et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. The Journal of infectious diseases 2005;191:856-65.

Nanteza MW, Mayanja-Kizza H, Charlebois E, et al. A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4(+) T-cell counts of >= 350 cells/muL. The Journal of infectious diseases 2011;204:884-92.

Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. The New England journal of medicine 1997;337:801-8.

Whalen CC. Failure of directly observed treatment for tuberculosis in Africa: a call for new approaches. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2006;42:1048-50.

Whalen CC, Zalwango S, Chiunda A, et al. Secondary attack rate of tuberculosis in urban households in Kampala, Uganda. PloS one 2011;6:e16137.

Martinez L, Shen Y, Isaacson S, Mupere E, Kizza A, Hill PC, Whalen CC. Estimating the Individual and Population-Level Impact of Household Tuberculosis Exposure on Transmission: A Systematic Review and Meta-Analysis. Am J Epidemiol. Accepted for publication. 2016.

Sekandi JN, Zalwango S, Martinez L, et al. Four Degrees of Separation: Social Contacts and Health Providers Influence the Steps to Final Diagnosis of Active Tuberculosis Patients in Urban Uganda. BMC infectious diseases 2015;15:361.

News/Media

TEDxUGA talk on tuberculosis and global health – https://www.youtube.com/watch?v=ELUeKUVIF-0